Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

BACKGROUND: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome. Later, meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan. METHODS: M...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, John R., Cairns, David A., Menzies, Tom, Pawlyn, Charlotte, Davies, Faith E., Sigsworth, Rachel, Brioli, Annamaria, Jenner, Matthew W., Kaiser, Martin F., Olivier, Catherine, Reed, Molly, Drayson, Mark T., Owen, Roger G., Boyd, Kevin D., Cook, Gordon, Morgan, Gareth J., Jackson, Graham H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404862/
https://www.ncbi.nlm.nih.gov/pubmed/37554123
http://dx.doi.org/10.1016/j.eclinm.2023.102099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404862/
https://www.ncbi.nlm.nih.gov/pubmed/37554123
http://dx.doi.org/10.1016/j.eclinm.2023.102099

Ejemplares similares